MTAP deficiency can also promote the formation of glioma stem cells (GSC), increase the expression of CD133 and enhance the tumorigenicity of glioblastoma cells, which is related to poor prognosis of patients (Hansen et al., 2019). Here, MTAP is linked to central nervous system cancer.